Maxigen Biotech Inc Cash Flow Conversion Efficiency
Maxigen Biotech Inc cash flow conversion efficiency. Based on the latest financial reports, Maxigen Biotech Inc (1783) has a cash flow conversion efficiency ratio of 0.050x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$74.75 Million ≈ $2.36 Million USD) by net assets (NT$1.50 Billion ≈ $47.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Maxigen Biotech Inc (2009–2025)
Cash flow conversion efficiency of Maxigen Biotech Inc from 2009 to 2025. This chart illustrates how Maxigen Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Maxigen Biotech Inc share price for real-time trading data and today's change.
Maxigen Biotech Inc Cash Flow Conversion Ratio Explained
Maxigen Biotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Maxigen Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maxigen Biotech Inc ranked by their cash flow conversion efficiency. Also see market cap of Maxigen Biotech Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Excel Cell Electronic Co Ltd
TW:2483
|
-0.003x |
|
CO2 Energy Transition Corp. Common Stock
NASDAQ:NOEM
|
-0.002x |
|
Dyaco International Inc
TW:1598
|
0.051x |
|
TMT Investments PLC
LSE:TMT
|
-0.003x |
|
Ester Industries Limited
NSE:ESTER
|
0.033x |
|
Scientex Packaging
KLSE:8125
|
0.042x |
|
HomesToLife Ltd
NASDAQ:HTLM
|
0.084x |
|
Serrano 61 Desarrollo SOCIMI SA
MC:YSRR
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Maxigen Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Maxigen Biotech Inc from 2009 to 2025. Review 1783 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.54 Billion ≈ $48.44 Million |
NT$290.22 Million ≈ $9.14 Million |
0.189x | -12.97% |
| 2024-12-31 | NT$1.38 Billion ≈ $43.32 Million |
NT$298.22 Million ≈ $9.40 Million |
0.217x | +72.42% |
| 2023-12-31 | NT$1.36 Billion ≈ $42.88 Million |
NT$171.20 Million ≈ $5.39 Million |
0.126x | -39.27% |
| 2022-12-31 | NT$1.30 Billion ≈ $40.82 Million |
NT$268.34 Million ≈ $8.45 Million |
0.207x | +101.08% |
| 2021-12-31 | NT$1.14 Billion ≈ $35.97 Million |
NT$117.59 Million ≈ $3.70 Million |
0.103x | +19.10% |
| 2020-12-31 | NT$860.23 Million ≈ $27.10 Million |
NT$74.39 Million ≈ $2.34 Million |
0.086x | -22.02% |
| 2019-12-31 | NT$851.32 Million ≈ $26.82 Million |
NT$94.42 Million ≈ $2.97 Million |
0.111x | -45.19% |
| 2018-12-31 | NT$842.98 Million ≈ $26.56 Million |
NT$170.58 Million ≈ $5.37 Million |
0.202x | +291.31% |
| 2017-12-31 | NT$796.25 Million ≈ $25.09 Million |
NT$41.18 Million ≈ $1.30 Million |
0.052x | +16.39% |
| 2016-12-31 | NT$781.38 Million ≈ $24.62 Million |
NT$34.72 Million ≈ $1.09 Million |
0.044x | +133.57% |
| 2015-12-31 | NT$829.86 Million ≈ $26.14 Million |
NT$-109.85 Million ≈ $-3.46 Million |
-0.132x | -703.35% |
| 2014-12-31 | NT$877.01 Million ≈ $27.63 Million |
NT$-14.45 Million ≈ $-455.29K |
-0.016x | +34.46% |
| 2013-12-31 | NT$888.39 Million ≈ $27.99 Million |
NT$-22.34 Million ≈ $-703.71K |
-0.025x | -155.33% |
| 2012-12-31 | NT$385.66 Million ≈ $12.15 Million |
NT$17.53 Million ≈ $552.17K |
0.045x | +121.89% |
| 2011-12-31 | NT$369.25 Million ≈ $11.63 Million |
NT$-76.64 Million ≈ $-2.41 Million |
-0.208x | -389.53% |
| 2010-12-31 | NT$395.39 Million ≈ $12.46 Million |
NT$-16.76 Million ≈ $-528.16K |
-0.042x | -168.87% |
| 2009-12-31 | NT$313.03 Million ≈ $9.86 Million |
NT$19.27 Million ≈ $607.14K |
0.062x | -- |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, d… Read more